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Resistance to endocrine treatment occurs in ~30% of ER+ breast cancer patients resulting in
~40,000 deaths/year in the USA. Preclinical studies strongly implicate activation of growth
factor receptor, HER2 in endocrine treatment resistance. However, clinical trials of pan-HER
inhibitors in ER+/HER2− patients have disappointed, likely due to a lack of predictive bio-
markers. Here we demonstrate that loss of mismatch repair activates HER2 after endocrine
treatment in ER+/HER2− breast cancer cells by protecting HER2 from protein trafficking.
Additionally, HER2 activation is indispensable for endocrine treatment resistance in MutL-
cells. Consequently, inhibiting HER2 restores sensitivity to endocrine treatment. Patient data
from multiple clinical datasets supports an association between MutL loss, HER2 upregula-
tion, and sensitivity to HER inhibitors in ER+/HER2− patients. These results provide strong
rationale for MutL loss as a first-in-class predictive marker of sensitivity to combinatorial
treatment with endocrine intervention and HER inhibitors in endocrine treatment-resistant
ER+/HER2− breast cancer patients.
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Estrogen receptor positive (ER
+) breast cancer is one of the
most common cancers in women worldwide1. ER+ breast
cancer patients are treated with endocrine therapy, which
interrupts ER signaling2. A subset of ER+ breast tumors also
amplify the tyrosine kinase receptor and oncogene, HER23,4.
These ER+/HER+ breast cancer patients are less responsive
to endocrine therapy but respond extremely well to combinatorial
treatment with HER inhibitors, a seminal discovery5.
However, the majority of ER+ breast cancer is HER2− at diag-
nosis, and while ~70% of ER+/HER2− breast cancer patients
respond well to endocrine therapy, ~30% of patients become
resistant to endocrine treatment resulting in relapse, metastasis,
and death2,6.
The discovery that HER2 amplification induces endocrine
therapy resistance in ER+ breast cancer spurred research into
other means of HER2 activation. These studies identified muta-
tion and phosphorylation as mechanisms by which ER+ HER2
non-amplified (henceforth referred to as ER+ HER2−) breast
cancer cells could activate HER2 signaling to resist endocrine
treatment4,7. However, translation of these findings proved
challenging with results from clinical trials failing to live up to
preclinical promise8,9. There is recognition now that this is likely
because only a subset of ER+ breast cancers activate HER2 to
resist endocrine therapy. Finding this subset is complicated by the
fact that ER+/HER2− breast cancer cells likely activate HER2
only in response to endocrine therapy, making identification of
these patient cohorts from diagnostic biopsies challenging.
Without identifying this patient subset, it is difficult to design a
clinical trial with sufficient resolution to uncover real improve-
ment in patient outcome.
Continuing efforts to identify alternate therapies for endocrine-
therapy-resistant ER+/HER2− breast cancer patients have largely
failed to show real improvement in the clinic. The only targeted
therapy to prove effective to date is CDK4/6 inhibitors10. How-
ever, these inhibitors have to be administered constantly to be
effective, and are, therefore, a financially and physically costly
treatment modality that postpones resistance, metastasis, and
death but does not remove this threat11. Moreover, some
endocrine-therapy-resistant patients do not respond to CDK4/6
inhibitors at all12. Hope of curing endocrine-therapy-resistant
patients with HER2 inhibitors, therefore, remains a tantalizing
challenge with clinical impact.
Defects in the MutL complex of mismatch repair, comprised of
MLH1 and PMS2, were recently identified as drivers of endocrine
treatment resistance in 15–17% of ER+/HER2− breast cancer
patients13,14. Mismatch repair is a fundamental DNA repair
pathway conserved between pro- and eukaryotes, and essential
for guarding the genome during cellular replication15. Here, we
demonstrate a non-genomic role for MutL loss in activating
HER2 in ER+ HER2− cells exposed to endocrine therapies.
Moreover, using multiple experimental model systems, we pro-
vide strong evidence for MutL loss as a stratifier of response to
HER inhibitors in endocrine-therapy-resistant, nominally HER2−
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Fig. 1 ER+, HER2− (non-amplified) breast cancer patients whose tumors are MutL− have elevated RNA levels of HER2 and associate with significantly
worse disease-specific survival. A Incidence of tumors with elevated HER2 RNA levels within MutL− and MutL+ ER+/HER2− breast tumors from
METABRIC (p= 0.0006) and TCGA. Pearson Chi-Square test identified p values. Corresponding RPPA data in Fig. S2A and contextualization with HER2+
subset in Fig. S2B, C. Kaplan–Meier survival curves (B) and proportional hazard assessment (C) demonstrating differences in disease-specific survival
between specified groups within the ER+/HER2− breast tumor cohort from METABRIC. Boxes in (C) indicate the hazard ratio calculated using the Cox
Proportional Hazards Regression analysis and error bars indicate the 95% confidence interval. Stage I p value= 0.0003. Supporting data from TCGA
presented in Fig. S2D and proliferation controls in Fig. S2E, F. All statistical tests were two-sided. Source data for this figure are available with paper.
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Results
Loss of mismatch repair associates with HER2 activation in
HER2− breast cancer cells. To understand mechanisms under-
lying MutL loss-induced endocrine treatment resistance, we
analyzed previously generated reverse phase protein array
(RPPA) data to compare ER+/HER2− MCF7 breast cancer cells
engineered to carry shRNA against MLH1 or PMS2 against
control isogenic cells with shRNA against Luciferase13. This
model system has been extensively validated using orthogonal
approaches, with pooled RNAi and with rescue using wild-type
MLH1 and is continually revalidated13,14. Analysis of the RPPA
data identified significant upregulation of phosphorylated HER2
(pHER2) in response to endocrine treatment (fulvestrant) in
shMLH1 and shPMS2 MCF7 cells but not in shLuc cells (Fig. S1).
To test whether an association between MutL loss and HER2
activation is also detectable in patient tumors, we analyzed HER2
protein levels from RPPA data in ER+ breast tumors that were
nominally HER2− (non-amplified) from TCGA. We observed
that ~70% of MutL− patient tumors have positive HER2 levels
compared to ~50% of MutL+ patient tumors (Fig. S2A). These
tumor samples are largely treatment-naïve, and therefore corre-
spond more closely to the RPPA data generated from vehicle-
treated controls in our model system, where we observe modest
upregulation of HER2 protein levels, than to the more robust
HER2 upregulation observed in fulvestrant-treated samples
(Fig. S1).
Encouraged by this observation, we compared RNA levels
using gene expression microarray data from two independent
patient tumor datasets: METABRIC and TCGA. We chose to
compare RNA levels as these data are more abundant in multiple
datasets and permit correlations with patient outcomes. In both
cases, we observed that ~25% of MutL− ER+/HER2− patient
tumors have relatively high RNA levels of HER2 compared to
~10% of MutL+ patient tumors (Fig. 1A). While neither RNA nor
protein levels in this heterogeneous collection of treatment-naïve
and pre-treated patient tumors are as high as that seen in HER2+
breast cancer (contextualized in Fig. S2B, C), nonetheless they
consistently show modest increase in total HER2 RNA and
protein levels in MutL− ER+/HER2− patient tumors.
MutL− patient tumors with relatively high HER2 RNA also
associate with significantly worse disease-specific survival in
METABRIC (Fig. 1B) and in TCGA (Fig. S2D). Upregulation of
HER2 in MutL− patient tumors also independently prognosticates
worse disease-specific survival in Cox Proportional Hazards
analyses when considering PR status, tumor stage, and TP53
mutational status as confounding variables (Fig. 1C). MutL loss as
assayed by low gene expression levels is not an artifact of low basal
proliferation since RNA levels of MKI67 (a proliferation marker)
are either higher in MutL− patient tumors, or comparable between
MutL− and MutL+ patient tumors (Fig. S2E, F). Together, these
data suggest that the association between MutL loss and HER2
upregulation is of clinical relevance.
Inhibition of mismatch repair activates HER2 in response to
endocrine treatment in ER+/HER2− breast cancer cells. We
next tested the causality of this relationship in two independent
cell line models of ER+/HER2− breast cancer: MCF7 and T47D.
Data from these experimental model systems mirror that
observed in patient datasets. In both cell lines, Western blotting
identified higher baseline levels of pHER2 in cells with stable
knockdown of MLH1 (shMLH1), the principal component of the
MutL complex, relative to isogenic MLH1-proficient (shLuc) cells,
with further increase upon treatment with ER degrader, fulves-
trant (Figs. 2A and S3A). Downstream signaling to pAkt and
pS6k is also upregulated in shMLH1 cells after fulvestrant
treatment (Fig. 2A). In addition, we confirmed increased HER2
protein at the membrane of shMLH1 cells after fulvestrant
treatment using both immunofluorescence (Fig. 2B) and flow
cytometry (Fig. S3B, C). Increase in membrane HER2 in shMLH1
cells after exposure to endocrine treatment was consistent in
xenograft tumors from MCF7 shLuc and shMLH1 cells (Fig. 2C).
This increase in membrane-bound HER2 remained consistent
with use of antibodies against either total HER2 (Fig. 2B) or
against pHER2 (Figs. 2C and S3E). Also, the same increase in
membrane HER2 levels after fulvestrant treatment was seen in
tumors from an ER+/HER2− patient-derived xenograft (PDX)
model of MutL loss (WHIM2013,16) (Fig. 2D). We did not
observe changes in levels of MLH1 protein in response to HER2
inhibition, validating the directionality of the observed relation-
ship (Fig. S3F). These data indicate that MutL loss directly acti-
vates HER2 signaling in ER+/HER2− breast cancer cells upon
endocrine treatment.
MutL− cells engage HER2 signaling by protecting HER2 from
lysosomal protein trafficking. Since MutL− ER+/HER2− tumors
have higher mutation load than MutL+ tumors13,17, we tested
whether HER2 activation in these tumors occurs via activating
mutations in HER2, a previously established mechanism of HER2
activation in HER2 non-amplified cancer cells7. We found no
enrichment for HER2 mutations in ER+/HER2− MutL− primary
patient tumors relative to MutL+ ones (TCGA: 0 vs. 1.8%,
METABRIC: 2.2% vs. 2.8% in MutL− vs. MutL+). Further, HER2
activation induced by loss of MLH1 in our experimental model
systems is reversible when MLH1 is re-expressed in shMLH1 cells
(Fig. S3D), arguing against an irreversible mutational change as
the underlying mechanism. In addition, acute loss of MLH1 by
transient transfection of parental MCF7 cells with sgRNA against
MLH1 immediately upregulates pHER2 to similar levels as those
seen in cells with stable knockdown of MLH1 (Fig. S3E). These
data both confirm the specificity of the link between MLH1 loss
and HER2 activation and argue against an underlying mechanism
of mutagenesis. This suggests that MutL loss activates HER2
through non-mutational mechanisms. To identify alternate
mechanisms by which MutL loss activates HER2 signaling in
conjunction with endocrine treatment, we conducted RNAseq
analysis of shMLH1 MCF7 cells relative to isogenic shLuc con-
trols at baseline and after fulvestrant treatment (Supplementary
Data 1). RNAseq analysis of signatures identified significant
enrichment of protein trafficking pathways in MutL− relative to
MutL+ cells after fulvestrant treatment (Fig. 3A). We found
similar enrichment for autophagy and protein trafficking path-
ways in Reactome analysis of RPPA data comparing MutL− and
MutL+ cells after fulvestrant treatment (Fig. S4A). Therefore, we
next tested whether loss of the MutL complex prevents the tar-
geting of HER2 for lysosomal degradation after endocrine therapy
in ER+/HER2− breast cancer cells.
First, we conducted a time course immunofluorescence
experiment testing colocalization of HER2 with the lysosomal
marker, LAMP1 in MCF7 and T47D shLuc and shMLH1 cells at
baseline and at 18, 36, and 54 h post treatment with fulvestrant.
At baseline and at 18 h post treatment, both shLuc and shMLH1
cells exhibit low levels of HER2, however by 36 h post treatment,
HER2 positivity increases in both cell types. However, 60–80% of
shLuc cells with HER2 expression demonstrate colocalization of
HER2 with LAMP1 (Figs. 3B and S4B). By 54 h post treatment,
HER2 continues to colocalize with LAMP1 in shLuc cells,
whereas shMLH1 counterparts have HER2 at the membrane,
distinct from the perinuclear LAMP1 immunostain (Fig. 3B).
Next, we used chloroquine, a known autophagy inhibitor18,19, to
test whether inhibition of lysosomal degradation pathways in
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shLuc cells can rescue HER2 positivity after endocrine therapy. In
both MCF7 and T47D cells, shLuc cells treated with a
combination of fulvestrant and chloroquine demonstrate sig-
nificant increase in membrane HER2 positivity relative to those
treated with fulvestrant alone (Figs. 3C and S4C). Indeed,
membrane HER2 positivity is at levels comparable to that of
shMLH1 counterparts in both cell lines tested, with the addition
of chloroquine.
Finally, we directly tested whether MutL loss prevents targeting
of HER2 to autophagosomes by assessing colocalization of
transiently transfected HER2-GFP and LC3-RFP for up to 36 h
after administration of fulvestrant in shLuc and shMLH1 MCF7
A B MCF7 cells 
C MCF7 xenograft tumors
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Fig. 2 MLH1 loss in ER+, nominally HER2− breast cancer cells upregulates membrane-bound HER2. A Western blots demonstrating increase in pHER2
and downstream signaling in shMLH1 MCF7 cells treated with fulvestrant relative to shLuc cells. Quantification of four independent replicates conducted
through ImageJ in accompanying dot plots. Validation in T47D cells in Fig. S3A. Immunofluorescent staining for HER2 in MCF7 shLuc and shMLH1 cells
in vitro (B), in MCF7 shLuc and shMLH1 xenograft tumors (C), and in WHIM20, PMS2 mutant, ER+/HER2− PDX tumors (D), grown with or without
fulvestrant. Accompanying quantification presented as strip charts. Three independent experiments or tumors from each group were quantified. Two-sided
Student’s t test determined p values. Supporting data from FACS analysis are presented in Fig. S3B, C. Scale bars represent 50 µ. Source data for all figures
available with paper.
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cells. While shLuc cells demonstrate increasing colocalization of
HER2 and LC3 with time after treatment with fulvestrant,
shMLH1 cells do not (Fig. 3D, E). In fact, by 36 h after fulvestrant
treatment, shMLH1 cells with defined membrane HER2 staining
are detectable with no LC3 colocalization, whereas this is
undetectable in shLuc counterparts (green arrows, Fig. 3E).
Together, these data indicate that both shLuc and shMLH1 ER+/
HER2− breast cancer cells upregulate HER2 upon ER degrada-
tion through endocrine therapy. However, while shLuc cells
rapidly target HER2 to lysosomal protein trafficking, shMLH1
cells maintain HER2 at the membrane, thereby upregulating
HER2-mediated signaling and inducing endocrine therapy
resistance.
HER2 is required for endocrine treatment resistance of MutL−
ER+/HER2− breast cancer cells. To test whether HER2 activa-
tion in MutL− cells is required for endocrine-therapy-resistant
growth, we used siRNA to decrease endogenous HER2 in
MCF7 shLuc and shMLH1 cells, and then assayed growth in
presence of fulvestrant. We observed complete rescue of endo-
crine treatment sensitivity in shMLH1 cells transfected with
siHER2, with no observable change in endocrine therapy response
A B MCF7 cellsRNAseq (MCF7 cells + fulvestrant)
C
MCF7 cells D




























































































































Fig. 3 MLH1 regulates protein trafficking of HER2. A Gene set enrichment analysis of RNAseq data comparing isogenic shLuc and shMLH1 MCF7 cells
after treatment with fulvestrant for 4 days. P values were generated using DESeq2 R package and adjusted for multiple comparison using
Benjamini–Hochberg. Comparable RPPA data analysis in Fig. S4A. Raw read counts available as supplementary data. B Co-immunofluorescence for HER2
and lysosomal marker, LAMP1 (orange arrows) at baseline and after 18, 36, and 54 h of fulvestrant treatment. Green arrows indicate HER2 that is not
colocalized with LAMP1, and red arrows indicate LAMP1 positivity alone. Validation in T47D cells in Fig. S4B. C Immunofluorescence staining for HER2 in
MCF7 shLuc and shMLH1 cells treated with vehicle and 36 h of fulvestrant alone or a combination of fulvestrant and chloroquine, an autophagy inhibitor. For
shLuc vs. shMLH1 vehicle, p= 0.0006. Validation in T47D cells in Fig. S4C. Quantification (D) and representative photomicrographs (E) from 36 h of live
cell tracking of colocalization of HER2 and LC3 (orange arrows), a marker of autophagosomes, in MCF7 shLuc and shMLH1 cells treated with vehicle or
fulvestrant. Green arrows indicate HER2+ LC3− cells. Cells were tracked after administration of fulvestrant. All quantification is of three independent
biological replicates conducted through ImageJ and is represented as strip charts. Two-sided Student’s t test determined all p values. For shLuc vehicle vs.
36-h fulvestrant treatment, p= 0.0003 and for shLuc vs. shMLH1 at 36-h fulvestrant treatment, p= 0.0005. Scale bars represent 50 µ. Source data for all
figures available with paper.
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in shLuc cells under the same conditions (Fig. 4A, B). This rescue
of sensitivity to endocrine therapy extends to tamoxifen
(Fig. S5A) and estrogen deprivation, a surrogate for aromatase
inhibitors (Fig. S5B). In keeping with this observation, both
MCF7 (Fig. 4C) and T47D (Fig. S5C) shMLH1 cells grown in 2D
are sensitive to combinatorial administration of fulvestrant and
lapatinib, a HER inhibitor used in clinic. In addition, MCF7
(Fig. 4D) and T47D (Fig. S5D) shMLH1 cells demonstrate
increased sensitivity to fulvestrant when treated with neratinib,
another HER inhibitor. Similar results were obtained when ner-
atinib was combined with tamoxifen treatment (Fig. S5E).
To test specificity of MLH1 loss in inducing therapeutic
vulnerability to HER2 inhibitors, we also tested growth response
to lapatinib in two previously established endocrine therapy
resistance models: MCF7 cells harboring either an ESR1-YAP1 or
an ESR1-PCDH11X fusion20. Both these model systems with no
known defects in mismatch repair are resistant to endocrine
therapy, fulvestrant, as expected, but remain resistant to lapatinib
compared to MCF7 shMLH1 cells (Fig. S5F). Finally, both MCF7
(Fig. 4E) and T47D (Fig. S6A) shMLH1 cells demonstrated
persistent 3D growth relative to shLuc cells in response to
fulvestrant, but this growth was significantly suppressed by
adding lapatinib.
These data suggest that loss of MutL predisposes ER+/HER2−
breast cancer cells to respond to HER inhibitors in concert with
endocrine therapies. To test this proposition in vivo, we
randomized mice with MCF7 shLuc and shMLH1 xenograft
tumors into five treatment arms: control (with estrogen
supplementation), estrogen deprivation, fulvestrant (and estrogen
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Fig. 4 HER2 is required for endocrine-therapy-resistant growth of ER+ MLH1− breast cancer cells. Knockdown of endogenous HER2 using siRNA against
HER2 or a scrambled control in MCF7 shLuc and shMLH1 cells validated by Western blotting (B) and followed by 2D growth assays for dose response to
fulvestrant treatment (A). For shLuc vs. shMLH1 with siScr, p= 0.0001. Supporting data demonstrating similar response to tamoxifen and estrogen
deprivation in Fig. S5A, B. C Growth of MCF7 shLuc and shMLH1 cells in response to specified therapeutic combinations represented as a bar graph. For shLuc
vs. shMLH1 with fulvestrant treatment, p= 0.0009, and for shMLH1 fulvestrant vs. lapatinib+ fulvestrant treatment, p= 3.15e− 05. Supporting data from
T47D in Fig. S5C. D Dose curve demonstrating response to neratinib and fulvestrant in MCF7 shLuc and shMLH1 cells. Supporting data demonstrating similar
results in T47D cells and in response to tamoxifen in Fig. S5D, E. E 3D growth in Matrigel of MCF7 shLuc and shMLH1 cells in response to specified
treatments. Representative images for each treatment group (except lapatinib, which showed no visible difference from vehicle-treated) shown alongside
quantification. For both shLuc vs. shMLH1 fulvestrant-treated, and shMLH1 fulvestrant vs. fulvestrant+ lapatinib-treated, p= 0.0002. Supporting data in
T47D cells in Fig. S6A. For dose curve experiments A, C, D three independent biological replicates were quantified for each group and each dose point. IC50
values were determined over three independent experiments and compared for statistical differences. Circles (A, D) represent mean growth relative to
vehicle-treated cells over 7 days of treatment and error bars the standard deviation. Box plots show median, quartiles, minima and maxima, and outliers at
1.5× IQR. All statistical comparisons used the two-sided Student’s t test. All experiments were conducted >2 times. Source data for this figure available
with paper.
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combination of fulvestrant and lapatinib (and estrogen depriva-
tion). As expected from previous experiments13, we observed
estrogen independent and fulvestrant-resistant growth in
MCF7 shMLH1 tumors, and little response to lapatinib alone
(Fig. 5A). However, there was striking response with tumor
shrinkage to the combination of fulvestrant and lapatinib
(Fig. 5A). In contrast, MCF7 shLuc tumors demonstrated tumor
shrinkage in response to either estrogen deprivation or fulvestrant
treatment alone and no further response to the addition of
lapatinib (Fig. 5B), in keeping with previous literature21–23.
Loss of mismatch repair increases sensitivity to HER inhibitors
in vivo and in patient tumors. We next tested whether MutL
defects had similar associations with sensitivity to HER
inhibitors in PDX tumors. In vivo growth of WHIM20, PMS2
mutant, ER+/HER2− PDX tumors xenografted into mouse
mammary fat pads demonstrated a similar pattern of tumor
regression in response to combination of lapatinib and fulves-
trant but not in response to either treatment alone (Fig. 5C). To
test whether loss of PMS2 causally activates HER2 and induces
response to HER2 inhibitors, similarly to MLH1, we tested our
previously established and validated MCF7 cells with stable
knockdown of PMS213 (Fig. S6B). We observed high baseline
levels of pHER2 in shPMS2 cells and further induction after
fulvestrant treatment (Fig. S6C). This upregulation of HER2
levels was reflected in increased sensitivity to HER inhibitor,
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Fig. 5 MLH1 loss predicts sensitivity to HER inhibitors in endocrine-therapy-resistant ER+, HER2− breast cancer cells in vivo and in patient tumors. In
vivo xenograft experiments of MCF7 shMLH1 (A), shLuc (B) cells, and WHIM20 PDX line (C) demonstrating response in tumor growth to specified
treatments. Control group: n= 5 mice; estrogen-deprived group: n= 4 (A), n= 5 (B), and n= 7 (C); lapatinib group: n= 6 (A), n= 5 (B), n= 4 (C);
fulvestrant group: n= 5 (A), n= 6 (B), n= 3 (C); fulvestrant+ lapatinib group: n= 8 (A), n= 6 (B), n= 5 (C). Circles represent the mean and error bars
the standard deviation. Student’s t test determined p values by comparing slopes. For (B), +E2 vs. fulvestrant+ lapatinib-treated tumors, p= 0.0005 and
for (C), fulvestrant+ lapatinib-treated tumors vs. rest, p= 4.7e− 05. D Immunofluorescence depicting protein levels of MLH1 in two ER+/HER2− PDX
lines associating with HER2 activation after estrogen deprivation. Scale bar= 50 µ. E Growth curves demonstrating sensitivity of these PDX lines to HER
inhibition ex vivo. IC50 calculated using regression analysis over three independent experiments and compared using two-sided Student’s t test. Circles
represent the mean and error bars the standard deviation. Supporting data in Fig. S7A, B. F Categorical analysis supporting increased sensitivity of
ER+/MutL− patient tumors to trastuzumab in combination with other chemotherapy. Supporting data in Fig. S7E, F. Y yes, Int intermediate, N no. Two-
sided Fisher’s Exact test determined p values. For all regression analyses, individual p values and multiple adjusted R2 values were derived using a linear
model in R. Source data available with paper.
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An additional ER+/HER2− PDX line24 with low MLH1 protein
(Fig. 5D) and lowMLH1 RNA levels (Fig. S7A) also has increased
membrane-bound HER2 (Fig. 5D). This increase in HER2 protein
at the membrane also associates with increased sensitivity to
BIBW2992 (or afatinib, a second generation pan-HER inhibitor),
as assayed by ex vivo 3D growth (Fig. 5E). We also observed
significant correlation between sensitivity to three HER inhibi-
tors, including lapatinib, and low RNA levels of MLH1/PMS2
across seven PDX models of luminal breast cancer24 grown in
estrogen-deprived conditions (Fig. S7A). Of note, there was no
such correlation across 11 PDX models of basal-like breast cancer
(Fig. S7B). Together, these data demonstrate that MutL loss
predisposes ER+/HER2− PDX tumors to respond to a combina-
tion of HER inhibitors and endocrine treatment.
We also validated our findings in transcriptomics data from
ER+/HER2− patient tumors biopsied at diagnosis and after
4–6 weeks of neoadjuvant aromatase inhibitor treatment
(Z103125). We first confirmed inverse association between RNA
levels of HER2 and MLH1 in these tumors at diagnosis (Fig. S7C),
indicating that tumors with low MLH1 have relatively higher HER2
at baseline (as observed in our experimental model systems and in
TCGA and METABRIC patient tumor datasets). Next, we identified
direct association between RNA levels of HER2 and proliferation as
measured by immunohistochemistry for Ki67 after endocrine
treatment (Fig. S7C). Importantly, this association is restricted to
MutL− tumors and not seen in tumors that are MutL+ (Fig. S7C).
These data suggest that loss of MutL induces HER2-associated
proliferation in ER+/HER2− breast cancer cells treated with
endocrine intervention. As an additional control, we found no
significant associations between levels of HER2 RNA and those of
another mismatch repair gene, MSH2, which is not part of the
MutL complex (Fig. S7D). This specificity increases confidence in
the association between HER2 activation and MutL loss. Second,
association between HER2 RNA levels and Ki67 in MutL− ER
+/HER2− breast tumors is only significant after exposure to
endocrine treatment and not in pre-treatment biopsies (Fig. S7D).
We confirmed that loss of MutL in patient tumors is not merely a
consequence of low proliferation (Fig. S7E). This attests to the
role of endocrine therapy in catalyzing reliance on HER2 for
proliferation in MutL− ER+/HER2− tumors.
We also analyzed a second dataset26 where metastatic,
treatment-resistant breast cancer patients, irrespective of
HER2 status, were randomized to two arms of treatment:
anthracyclines and taxanes or anthracyclines, taxanes and
trastuzumab, a HER2 inhibitor. From this dataset, we parsed
the subset of patients whose cancer was ER+/HER2− for further
analysis. Strikingly, all patients with MutL− ER+/HER2− breast
cancer demonstrate at least partial response to trastuzumab,
compared to less than half of patients with MutL+ ER+/HER2−
disease (Fig. 5F). In addition, 2/3rd of MutL− patients has
complete response to the trastuzumab combination compared to
less than a tenth of MutL+ patients (Fig. 5F). This disparate
response was only observed in the treatment group where
trastuzumab was added to the chemotherapy administered to
patients. Concomitant downregulation of HER2 RNA in response
to the trastuzumab combination, but not in response to
anthracyclines/taxanes alone was confirmed in the MutL− ER
+/HER2− tumors (Fig. S7F). These data, while of small sample
size, provide support for a role for MutL loss in sensitizing
endocrine-therapy-resistant ER+/HER2− breast cancer to a
combination of HER inhibitors and endocrine therapy.
Discussion
Taken together, results presented here suggest that MLH1/PMS2
downregulation could constitute a first-in-class predictive marker
for response to HER2 inhibition in endocrine-therapy-resistant
ER+/HER2− breast cancer. The only other biomarkers proposed
to predict response to HER2 inhibitors in the endocrine-therapy-
resistant ER+/HER2− setting are low ER/PR but these markers
are not specific to HER2 activation and have mixed associations
across clinical trials decreasing their feasibility for clinical use8,27.
The impact of the discovery presented here could be substantial,
given that loss of nuclear MLH1 and PMS2 occurs in 15–17% of
ER+/HER2− breast cancer28. Importantly, it is clinically feasible
to assess these markers at diagnosis to tailor therapy since diag-
nostic assays for MLH1 and PMS2 loss are routinely implemented
in clinic for colorectal and endometrial cancer patients29,30.
Coopting these diagnostic tests for ER+/HER2− breast cancer
patients is, therefore, relatively straightforward and could benefit
a significant subset of patients.
The mechanism underlying HER2 activation in response to
endocrine therapy in MutL− ER+/HER2− breast cancer cells is
through lysosomal protein trafficking. Data from Western blots
and immunofluorescence of cell lines and PDX tumors suggest
that total HER2 levels increase with MutL loss even before
endocrine therapy. Concordantly, baseline levels of HER2 appear
higher in ER+/HER2− MutL− breast cancer cells in patient
tumor gene expression data, although many orders lower than
levels in HER2-amplified patient tumors. These data suggest that
even at baseline, MutL− cells are less likely to target HER2 for
protein degradation. However, with endocrine therapy, HER2 is
upregulated in both MutL+ and MutL− ER+/HER2− breast
cancer cells as predicted by the literature3. In the context of this
HER2 upregulation, the protection of HER2 from protein traf-
ficking in MutL− cells allows HER2-mediated growth signaling to
compensate as a cell-cycle cue for the loss of ER driven by
standard endocrine therapies. These data provide an explanation
for the lack of positive clinical trial data from using HER inhi-
bitors in the endocrine-therapy-resistant ER+/HER2− breast
cancer setting, in spite of strong preclinical links between ER loss
and upregulation of HER23,4. The link between loss of a DNA
damage repair pathway and targeting of growth factor proteins
for protein trafficking requires further investigation.
A significant limitation of this study is the lack of specific
clinical trial data with which to test the hypothesis raised by the
molecular biology described above. Very few clinical trials have
been performed to test efficacy of HER inhibitors in ER+/HER2−
breast cancer patients8,31. None of these trials include tran-
scriptomic or genomic data accrual from tumor biopsies and
since MutL status is not routinely tested in clinic for breast cancer
patients, this data is missing from all existing trials. The strength
of preclinical data presented here and the strong associations
observed in the limited clinical trial data available make a com-
pelling case for revisiting HER inhibitors in the ER+/HER2−
breast cancer setting but this time in context of MutL status.
These results also have significance beyond ER+ breast cancer.
Our data provide support for a recent report on Lynch syndrome
colorectal cancer suggesting a link between loss of mismatch
repair and response to HER inhibitors32. Lynch syndrome is one
of the most common causes of inherited cancers at many sites
and is caused by hereditary defects in mismatch repair genes33. In
addition, mismatch repair loss drives a significant proportion of
sporadic colorectal, ovarian, and endometrial cancer34. If
MLH1/PMS2 loss serves as a predictive marker for sensitivity to
HER inhibitors across cancer types, the already routine identifi-
cation of these markers in these other cancer types can be married
to a clinically feasible targeted therapy.
Methods
Cell lines, mice, CRISPR, si/shRNA transfection, and growth assays. Cell lines
were obtained from the ATCC (2015) and maintained and validated as previously
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reported35. Mycoplasma tests were performed on parent cell lines and stable cell
lines every 6 months (latest test: 02/19) with the Lonza Mycoalert Plus Kit (cat#
LT07-710) as per the manufacturer’s instructions. Cell lines were discarded at <25
passages, and fresh vials were thawed out. Key experiments were repeated with
each fresh thaw. Transient transfection with siRNA against HER2 was conducted
using JetPrime PolyPlus transfection reagent35, and siRNA pools were purchased
from Sigma-Aldrich. Stable cell lines were maintained in presence of specified
antibiotics at recommended concentrations. Knockdown was validated using qRT-
PCR (list of primers used in Supplementary Table 1) and/or Western blotting.
Growth assays were conducted in triplicate and repeated independently using
Alamar blue to identify cell viability13. Growth assay results were plotted as fold
change in growth from day 1 to day 7 and normalized as specified. Three-
dimensional growth assays were conducted over 4–6 weeks with weekly drug
treatments using standard protocols7. Images were captured when colonies had
established (at 2 weeks), and then treatment was administered, with images taken
again at 1 and 3 weeks post treatment. Fold change in area of colonies was cal-
culated over time and represented as %growth. Tumor growth assays in vivo were
carried out by injecting 2–5 × 106 MCF7 cells into the L4 mammary fat pad/mouse.
Mice for the MCF7 experiments were 4- to 6-week athymic nu/nu female mice
(Envigo or SBP animal facility). For WHIM20 PDX experiments, 6- to 8-week
female SCID/Bg mice were purchased from Jackson laboratory. Tumor volume was
measured twice or thrice weekly using calipers to make 2 diametric measurements.
Tumors were randomized for treatment at 50–150-mm3 volume for MCF7
xenografts and 100–300-mm3 volume for WHIM20 PDX experiments. Tumors
were harvested at <2-cm diameter and were embedded in paraffin blocks, OCT,
and snap-frozen36. Mice that died within 3 weeks of tumor growth rate experi-
ments were excluded from analysis. For all mouse experiments, investigator was
blinded to groups and to outcomes. STG335, STG143, and VHIO244 PDX
experiment results were kindly provided by the BCaPE consortium, but tumor
sections were stained in house. All mouse experiments were performed in com-
pliance with all relevant ethical regulations for animal testing and research, and all
experiments conducted in the study received approval from the respective Insti-
tutional Animal Care and Use Committee boards (protocols# AN-6934 for Baylor
College of Medicine and 18-065 for Sanford Burnham Prebys).
Inhibitors and agonists. All drugs were maintained as stock solutions in DMSO,
and stock solutions were stored at −80 and working stocks at −20 unless otherwise
mentioned. 4-OHT (Sigma-Aldrich, cat# H7904) and fulvestrant (SelleckChem,
cat# I4409) were purchased, and stocks were diluted to 10-mmol/L working stocks
for all experiments other than dose curves, where specified concentrations were
used. For all experiments, cells were treated 24 h after plating, and thereafter every
48 h until completion of experiment. For mouse xenograft experiments, fulvestrant
concentrations of 250-mg/kg body weight were prepared in corn oil, freshly on day
of injection and administered subcutaneously. Beta-estradiol was purchased from
Sigma-Aldrich (cat# E8875), maintained in sterile, nuclease-free water, and diluted
to obtain 10-mmol/L stocks for in vitro experiments. For mouse xenograft
experiments, 17 β-estradiol was maintained in 200-proof ethanol at 2.7-mg/ml
stock solution and added to drinking water twice a week at a final concentration of
8 μg/mL (cat# E2758; Sigma). For experiments involving Chloroquine (Sell-
eckchem, cat#S4157), cells were treated at 50 μM for 16 h before end of assay.
Lapatinib (SelleckChem, cat#S2111) and Neratinib were used at specified con-
centrations. Lapatinib tablets were used at 100 mg/kg in chow from Research Diets,
Inc for tumor growth assays.
Flow cytometry, immunostaining, and microscopy. Flow cytometry for
membrane-bound HER2 was performed based on manufacturer’s instructions. After
fulvestrant treatment, cells were detached from plates using StemPro™ Accutase™ Cell
Dissociation Reagent (cat#A1110501). Cells were washed with chilled PBS and
suspended in antibody solution, as per the manufacturer’s instructions, in 5-mL flow
cytometry tubes and incubated on ice for 20min. Live cells were then run through
BD Accuri C6 cytometer to assess only membrane-bound HER2 protein levels. IF
was performed based on the manufacturer’s instructions. Cells were washed in PBS;
fixed for 20min at room temperature in 4% PFA; blocked for 1 h at room tem-
perature in 5% goat serum and 1% Triton X-100 in 1x PBS; incubated with primary
antibody overnight at 4° in 1% goat serum and 1% Triton X-100 in 1x PBS antibody
diluent; incubated with secondary antibody in diluent for 1 h at RT; and then
mounted with DAPI-containing mounting media (cat# P36935). Tumor section
staining was done using a standard protocol. Briefly, slides were incubated at 65° for
4 h and deparaffinized. Antigen retrieval was done with 10-mM Sodium Citrate (pH
6) for 25min in pressure cooker. Hereafter, the cells were treated the same as the 2D
IF. Primary antibodies used include pHER2 (EMD millipore; cat# 06-229; 1:200) and
Ki67 (Novus Biologics, cat# NB500-170SS, 1:250). Cells were treated with fulvestrant
for 24 h before evaluation. Fluorescent images were captured with a Nikon micro-
scope and quantified with ImageJ. Representative images were translated into figures
using Adobe Photoshop and Adobe Illustrator.
RNAseq analyses. RNAseq data were generated from two replicates each of
MCF7 shLuc and shMLH1 cells treated with either vehicle or 100-nM fulvestrant
for 4 days on the Illumina NovaSeq platforms with paired-end 150-bp sequencing.
Downstream analysis was performed using a combination of programs including
STAR, HTseq, Cufflink, and Novogene’s wrapped scripts. Alignments were parsed
using STAR program and differential expressions were determined through
DESeq2/edgeR. FPKM of each gene was calculated based on the length of the gene
and read counts mapped to this gene. GO and KEGG enrichment were imple-
mented by the ClusterProfiler. Source data available in supplementary files.
Lysosomal analyses. Immunofluorescence of LAMP1/HER2 was conducted by
plating 20k cells per well/per condition in a 96-well plate and treated with 100-nM
fulvestrant (SelleckChem, cat# I4409) for 36 h. Cells were then probed ON at 4 °C
with LAMP1 (proteintech, cat# 21997-1-AP) and HER2 (Invitrogen, cat# MA5-
13105) antibodies used at a 1:750 and 1:250 dilution, respectively, diluted in 1x
TBST with 5% Goat Serum. For HER2 and LC3 immunofluorescent images, cells
were transiently transfected with mCherry-hLC3B-pcDNA3.1, a gift from David
Rubinsztein (Addgene plasmid # 40827; http://n2t.net/addgene:40827; RRID:
Addgene_40827) and pCMV3-C-GFPSpark-HindIII-XbaI (SinoBiological, cat#
HG10004-ACG) using jetPRIME transfection reagent (Polyplus, cat#114-07) as per
manufacturers’ instructions. Thirty-six hours 100-nM Fulvestrant treatment started
16 h after transfection. Both assays were imaged using BioTek Cytation 5 Imaging
Reader.
Protein analyses. Western blotting was conducted as described35. Cells were
exposed to 18–24 h of fulvestrant treatment administered 40 h after plating. For
pHER2 Western blots, primary antibody was incubated for 48 h at 4°. For all other
antibodies, primary incubation was 2 h at room temperature. All antibodies diluted
in 1x TBST and incubated overnight at 4 °C. Antibodies used were pHER2 Y1196
(D66B7) (Cell Signaling; cat# 6942S), total HER2 (Thermo Scientific; NeoMarkers;
cat# MS-730-P1ABX), pAkt S473 (D9E) XP (Cell Signaling; cat#4060S), total Akt
(Cell Signaling; cat#9272S), pS6 (S235/236) (Cell Signaling; cat# 2211S), total S6
(5G10) (Cell Signaling; cat# 2217S), MLH1 (1:2,000, Sigma-Aldrich; cat#
WH0004292M2), ER clone 60C (EMD Millipore; cat# 04-820), and GAPDH
(0411) (Santa Cruz; cat# sc-47724). Unless otherwise specified, primary antibodies
were diluted 1:1000 for Western blotting. RPPA assays were carried out as
described previously with minor modifications37.
Statistical analysis. ANOVA or Student t test was used for independent samples
with normal distribution. Where distribution was not normal (assessed using Q–Q
plots with the Wilk–Shapiro test of normality), either the Kruskal–Wallis or
Wilcoxon Rank Sum test was used. All experiments were conducted in triplicate,
and each experiment was duplicated independently >2 times. These criteria were
formulated to ensure that results from each dataset were calculable within the range
of sensitivity of the statistical test used. Databases used for human data mining are
from publically available resources: Oncomine, cBio38, and COSMIC. Z1031
dataset was used with permission from the Alliance consortium. All patients
provided informed consent, and studies were conducted according to ethical
guidelines and with Institutional Review Board approval from each of the insti-
tutions involved in this previously published study. MutL− tumor from
METABRIC, TCGA, and Z1031 datasets was determined in a case list containing
all ER+ sample IDs based on gene expression less than mean—1.5 × standard
deviation and/or the presence of nonsilent mutations in MLH1 and PMS2. For the
multivariate analysis, we analyzed ER+ tumor samples, extracting mutation data
from the cBio portal, and corresponding clinical data through Oncomine. Only
samples with survival metadata were included in the analysis. Gene expression, and
survival data for TCGA samples were downloaded from cBio portal. All survival
data were analyzed using Kaplan–Meier curves and log-rank tests. Proportional
hazards were determined using Cox regression. Sample size for animal experiments
was estimated using power calculations in R. P values were adjusted for multiple
comparisons where appropriate using Benjamini–Hochberg. All graphs and sta-
tistical analyses were generated either in MS Excel or R and edited in Adobe
Photoshop or Illustrator. Z1031ClinicalTrials.gov Identifier: NCT00265759. Data
for Z1031 samples available in dbGaP (phs000472.v2.p1).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The patient datasets analyzed during the current study are all publicly available from
cBio data portal at cbioportal.org (TCGA and METABRIC), or from Gene Expression
Omnibus (GEO) (https://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-28826/).
Z1031 ClinicalTrials.gov Identifier: NCT00265759. Data for Z1031 samples available in
dbGaP (phs000472.v2.p1). Raw read count data from RNAseq that support the findings
of this study are available in Supplementary data. Source data are provided with
this paper.
Received: 15 September 2020; Accepted: 22 April 2021;
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-23271-0 ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:2940 | https://doi.org/10.1038/s41467-021-23271-0 |www.nature.com/naturecommunications 9
References
1. ACS. Facts and figures 2017–2018. https://www.cancer.org/content/dam/
cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-
figures/breast-cancer-facts-and-figures-2017-2018.pdf.
2. Ellis, M. J. Lessons in precision oncology from neoadjuvant endocrine therapy
trials in ER+ breast cancer. Breast https://doi.org/10.1016/j.breast.2017.06.039
(2017).
3. Schiff, R. et al. Cross-talk between estrogen receptor and growth factor
pathways as a molecular target for overcoming endocrine resistance. Clin.
Cancer Res. Off. J. Am. Assoc. Cancer Res. 10, 331S–336S (2004).
4. Fu, X., De Angelis, C., Veeraraghavan, J., Osborne, C. K. & Schiff, R.
Molecular mechanisms of endocrine resistance. in Estrogen Receptor and
Breast Cancer: Celebrating the 60th Anniversary of the Discovery of ER (ed
Zhang, X.) 265–307 (Springer International Publishing, 2019). https://doi.org/
10.1007/978-3-319-99350-8_11.
5. Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against
HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med.
344, 783–792 (2001).
6. Ellis, M. J. & Perou, C. M. The genomic landscape of breast cancer as a
therapeutic roadmap. Cancer Discov. 3, 27–34 (2013).
7. Bose, R. et al. Activating HER2 mutations in HER2 gene amplification
negative breast cancer. Cancer Discov. 3, 224–237 (2013).
8. Finn, R. S. et al. Estrogen receptor, progesterone receptor, human epidermal
growth factor receptor 2 (HER2), and epidermal growth factor receptor
expression and benefit from lapatinib in a randomized trial of paclitaxel with
lapatinib or placebo as first-line treatment in HER2-negative or unknown
metastatic breast cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 27,
3908–3915 (2009).
9. Ma, C. X. et al. A Phase II Trial of neoadjuvant MK-2206, an AKT inhibitor,
with anastrozole in clinical stage II or III PIK3CA-mutant ER-positive and
HER2-negative breast cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.
23, 6823–6832 (2017).
10. Beaver, J. A. et al. FDA approval: palbociclib for the treatment of
postmenopausal patients with estrogen receptor-positive, HER2-negative
metastatic breast cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.
https://doi.org/10.1158/1078-0432.CCR-15-1185 (2015).
11. Anurag, M., Ellis, M. J. & Haricharan, S. DNA damage repair defects as a new
class of endocrine treatment resistance driver. Oncotarget 9, 36252–36253
(2018).
12. Portman, N. et al. Overcoming CDK4/6 inhibitor resistance in ER-positive
breast cancer. Endocr. Relat. Cancer 26, R15–R30 (2019).
13. Haricharan, S. et al. Loss of MutL disrupts Chk2-dependent cell cycle control
through CDK4/6 to promote intrinsic endocrine therapy resistance in primary
breast cancer. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-16-1179
(2017).
14. Anurag, M. et al. Comprehensive profiling of DNA repair defects in breast
cancer identifies a novel class of endocrine therapy resistance drivers. Clin.
Cancer Res. Off. J. Am. Assoc. Cancer Res. 24, 4887–4899 (2018).
15. Brown, T. C. & Jiricny, J. Repair of base-base mismatches in simian and
human cells. Genome 31, 578–583 (1989).
16. Wardell, S. E. et al. Efficacy of SERD/SERM Hybrid-CDK4/6 inhibitor
combinations in models of endocrine therapy-resistant breast cancer. Clin.
Cancer Res. Off. J. Am. Assoc. Cancer Res. 21, 5121–5130 (2015).
17. Haricharan, S., Bainbridge, M. N., Scheet, P. & Brown, P. H. Somatic mutation
load of estrogen receptor-positive breast tumors predicts overall survival: an
analysis of genome sequence data. Breast Cancer Res. Treat. 146, 211–220
(2014).
18. Mauthe, M. et al. Chloroquine inhibits autophagic flux by decreasing
autophagosome-lysosome fusion. Autophagy 14, 1435–1455 (2018).
19. Solomon, V. R. & Lee, H. Chloroquine and its analogs: a new promise of an
old drug for effective and safe cancer therapies. Eur. J. Pharmacol. 625,
220–233 (2009).
20. Lei, J. T. et al. Functional annotation of ESR1 gene fusions in estrogen
receptor-positive breast cancer. Cell Rep. 24, 1434–1444.e7 (2018).
21. Scaltriti, M. et al. Expression of p95HER2, a truncated form of the HER2
receptor, and response to anti-HER2 therapies in breast cancer. J. Natl. Cancer
Inst. 99, 628–638 (2007).
22. Dupouy, S. et al. Activation of EGFR, HER2 and HER3 by neurotensin/
neurotensin receptor 1 renders breast tumors aggressive yet highly responsive
to lapatinib and metformin in mice. Oncotarget 5, 8235–8251 (2014).
23. Morrison, G. et al. Therapeutic potential of the dual EGFR/HER2 inhibitor
AZD8931 in circumventing endocrine resistance. Breast Cancer Res. Treat.
144, 263–272 (2014).
24. Bruna, A. et al. A biobank of breast cancer explants with preserved intra-
tumor heterogeneity to screen anticancer compounds. Cell 167, 260–274.e22
(2016).
25. Ellis, M. J. et al. Randomized phase II neoadjuvant comparison between
letrozole, anastrozole, and exemestane for postmenopausal women with
estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker
outcomes and predictive value of the baseline PAM50-based intrinsic
subtype–ACOSOG Z1031. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 29,
2342–2349 (2011).
26. Vera-Ramirez, L. et al. Oxidative stress status in metastatic breast cancer
patients receiving palliative chemotherapy and its impact on survival rates.
Free Radic. Res. 46, 2–10 (2012).
27. Finn, R. S. et al. Quantitative ER and PgR assessment as predictors of
benefit from lapatinib in postmenopausal women with hormone
receptor–positive, HER2-negative metastatic breast cancer. Clin. Cancer Res.
20, 736–743 (2014).
28. Fusco, N. et al. Mismatch repair protein loss as a prognostic and predictive
biomarker in breast cancers regardless of microsatellite instability. JNCI
Cancer Spectr. 13, pky056, https://www.ncbi.nlm.nih.gov/pubmed/31360876
(2018).
29. Lanza, G. et al. Immunohistochemical pattern of MLH1/MSH2 expression is
related to clinical and pathological features in colorectal adenocarcinomas
with microsatellite instability. Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc.
15, 741–749 (2002).
30. Stelloo, E. et al. Practical guidance for mismatch repair-deficiency testing in
endometrial cancer. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 28, 96–102
(2017).
31. Burstein, H. J. et al. Endocrine therapy with or without inhibition of epidermal
growth factor receptor and human epidermal growth factor receptor 2: a
randomized, double-blind, placebo-controlled phase III trial of fulvestrant
with or without lapatinib for postmenopausal women with hormone receptor-
positive advanced breast cancer-CALGB 40302 (Alliance). J. Clin. Oncol. Off.
J. Am. Soc. Clin. Oncol. 32, 3959–3966 (2014).
32. Kloth, M. et al. Activating ERBB2/HER2 mutations indicate susceptibility to
pan-HER inhibitors in Lynch and Lynch-like colorectal cancer. Gut 65,
1296–1305 (2016).
33. Win, A. K. et al. Risks of colorectal and other cancers after endometrial
cancer for women with Lynch syndrome. J. Natl Cancer Inst. 105, 274–279
(2013).
34. Ghanipour, L., Jirström, K., Sundström, M., Glimelius, B. & Birgisson, H.
Associations of defect mismatch repair genes with prognosis and heredity in
sporadic colorectal cancer. Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br.
Assoc. Surg. Oncol. 43, 311–321 (2017).
35. Haricharan, S. & Brown, P. TLR4 has a TP53-dependent dual role in
regulating breast cancer cell growth. Proc. Natl. Acad. Sci. USA 112,
E3216–E3225 (2015).
36. Haricharan, S. et al. Mechanism and preclinical prevention of increased breast
cancer risk caused by pregnancy. eLife 2, e00996 (2013).
37. Chang, C.-H. et al. Mammary stem cells and tumor-initiating cells are more
resistant to apoptosis and exhibit increased DNA repair activity in response to
DNA damage. Stem Cell Rep. 5, 378–391 (2015).
38. Cerami, E. et al. The cBio Cancer Genomics Portal: an open platform for
exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404
(2012).
Acknowledgements
We would like to acknowledge the Patient-derived Xenograft and Advanced In Vivo
Models core (funded by P30 Cancer Center Support Grant NCI-CA125123, CPRIT Core
Facilities Support Grant RP170691) and Dr Michael T. Lewis, Ph.D., Academic Director,
Lacey E. Dobrolecki, MS, Core Director at Baylor College of Medicine for helping us in
engrafting WHIM20 PDX explants. We also thank Dr Alejandra Bruna (CRUK, UK) and
Dr Violeta Serra (VHIO, Barcelona) for providing PDX drug response data and tumor
sections for the STG and VHIO PDX lines. Work in this study was funded by Depart-
ment of Defense Breast Cancer Research Program Breakthrough awards (W81XWH-18-
1-0034 to S.H., W81XWH-18-1-0035 to S.M.K.), NCI K22 Career Development award
(CA229613 to S.H.), Susan G. Komen Promise Grant (PG12220321 to M.J.E.), SPORE
grant (P50CA186784-06), and Cancer Prevention and Research Institute of Texas
(CPRIT) Recruitment of Established Investigators award (RR140033 to M.J.E.), National
Cancer Institute of the National Institutes of Health under Award Numbers
U10CA180821 and U10CA180882 (to the Alliance for Clinical Trials in Oncology),
U24C196171.
Author contributions
N.B.P. designed and performed experiments, analyzed data, and helped write the
manuscript. S.S. helped design, conduct, and analyze data from Western blots and
xenograft experiments. V.D. and A.M. helped design and conduct 3D Matrigel assays and
immunofluorescence experiments. S.L., T.P., R.K. and C.-H.C. conducted WHIM20
patient-derived xenograft experiment. M.J.E. and S.M.K. helped design experiments and
interpret results, and edit the manuscript. S.H. designed and performed experiments,
analyzed and interpreted data, and wrote and edited the manuscript.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-23271-0
10 NATURE COMMUNICATIONS |         (2021) 12:2940 | https://doi.org/10.1038/s41467-021-23271-0 | www.nature.com/naturecommunications
Competing interests
M.J.E. has intellectual property ownership and received royalties for the PAM50-based
breast cancer test “Prosigna.” In the last 5 years he has received ad hoc consulting fees and
meals (<$5000 per year) from Abbvie, Novartis, AstraZenica, Pfizer, Sermonix, and Puma.
S.M.K. is a stakeholder in NeoZenome Therapeutics Inc. S.L. has received license fee from
Envigo. He received research funding from Pfizer, Takeda Oncology, Zenopharm, NIH,
and DOD, outside of this project. The other authors declare no competing interests.
Additional information
Supplementary information The online version contains supplementary material
available at https://doi.org/10.1038/s41467-021-23271-0.
Correspondence and requests for materials should be addressed to S.M.K. or S.H.
Peer review information Nature Communications thanks Sarah Martin and the other
anonymous reviewer(s) for their contribution to the peer review of this work. Peer
reviewer reports are available.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2021
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-23271-0 ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:2940 | https://doi.org/10.1038/s41467-021-23271-0 |www.nature.com/naturecommunications 11
